Biofil Chemicals & Pharmaceuticals Ltd. (IN:BIOFILCHEM)
:BIOFILCHEM
Want to see IN:BIOFILCHEM full AI Analyst Report?
BIOFILCHEM Stock Chart & Stats
₹33.59
-₹0.32(-0.55%)
At close: 4:00 PM EST
₹33.59
-₹0.32(-0.55%)
Day’s Range― - ―
52-Week Range₹25.60 - ₹56.36
Previous CloseN/A
Volume25.08K
Average Volume (3M)6.87K
Market Cap
₹547.61M
Enterprise Value₹554.75M
Total Cash (Recent Filing)₹3.59M
Total Debt (Recent Filing)₹200.00K
Price to Earnings (P/E)172.4
Beta1.56
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding16,273,800
10 Day Avg. Volume7,559
30 Day Avg. Volume6,869
Financial Highlights & Ratios
PEG Ratio-5.50
Price to Book (P/B)3.72
Price to Sales (P/S)2.09
P/FCF Ratio-34.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthManageable leverage and a strong equity ratio provide structural financial resilience. Over a 2-6 month horizon this supports the firm's ability to absorb industry shocks, access funding on better terms, and prioritize strategic spending without immediate refinancing pressure.
Operating ProfitabilityConsistent positive EBIT/EBITDA margins and stable gross margins indicate durable operating efficiency and some pricing or cost advantage in specialty/generic pharmaceuticals. This supports sustained cash generation potential and reinvestment capacity over the medium term.
Positive Return On EquityA positive ROE reflects the company's ability to generate shareholder returns from deployed capital. Even with variability, persistent positive ROE signals competent capital allocation and operational leverage that can compound returns if maintained over coming quarters.
Bears Say
Revenue DeclineA steep revenue decline materially reduces scale and weakens the firm's competitive position. Over several months this compresses operating leverage, constrains margins, and limits funds available for R&D, marketing, or capacity investments that support long-term growth.
Weak Cash Flow QualityInconsistent operating cash generation and negative FCF growth signal structural liquidity pressure. Persisting over months, this limits self-funded investment, may force external financing, and raises risk to operations or strategic initiatives if capex remains elevated.
Earnings VolatilityVery large EPS swings indicate earnings are driven by one-off items or a small base, creating forecasting uncertainty. Persistent volatility complicates capital allocation, investor confidence, and long-term planning, reducing predictability of returns over the medium term.
Biofil Chemicals & Pharmaceuticals Ltd. News
BIOFILCHEM FAQ
What was Biofil Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
Biofil Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹25.60 and its highest was ₹56.36 in the past 12 months.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s market cap?
Biofil Chemicals & Pharmaceuticals Ltd.’s market cap is ₹547.61M.
When is Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 35 days.
How were Biofil Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
Biofil Chemicals & Pharmaceuticals Ltd. released its earnings results on Feb 13, 2026. The company reported ₹0.049 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.049.
Is Biofil Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Biofil Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Biofil Chemicals & Pharmaceuticals Ltd. pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd. does not currently pay dividends.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofil Chemicals & Pharmaceuticals Ltd. have?
Biofil Chemicals & Pharmaceuticals Ltd. has 16,273,800 shares outstanding.
What happened to Biofil Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Biofil Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹0.049 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.921%.
Which hedge fund is a major shareholder of Biofil Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:BIOFILCHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.
Technical Analysis
Bal Pharma Limited
―
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Vaishali Pharma Ltd.
―